Rifapentine access in Europe: growing concerns over key tuberculosis treatment component

Guglielmetti Lorenzo; Gunther Gunar; Leu Claude; Chesov Dumitru; Noi Autori

Conţinutul numărului revistei

Articolul precedent

Articolul urmator

171

SM ISO690:2012

GUGLIELMETTI, Lorenzo, GUNTHER, Gunar, LEU, Claude, CHESOV, Dumitru, NOI, Autori. Rifapentine access in Europe: growing concerns over key tuberculosis treatment component. In: European Respiratory Journal, 2022, vol. 59, p. 0. ISSN 0903-1936. DOI: https://doi.org/10.1183/13993003.00388-2022

EXPORT metadate:
Google Scholar
Crossref
CERIF

DataCite
Dublin Core

European Respiratory Journal

Volumul 59 / 2022 / ISSN 0903-1936 /ISSNe 1399-3003

Rifapentine access in Europe: growing concerns over key tuberculosis treatment component

DOI:https://doi.org/10.1183/13993003.00388-2022

Pag. 0-0

Guglielmetti Lorenzo¹, Gunther Gunar²³⁴, Leu Claude², Chesov Dumitru, Noi Autori

¹ Sorbonne University,
² University of Bern,
³ University of Namibia, School of Medicine, Windhoek,
⁴ Hôpital Avicenne

Disponibil în IBN: 19 iulie 2023

Cuvinte-cheie
MeSH Antibiotics, Antitubercular, Antitubercular Agents, drug therapy, Combination, Europe, Humans, Rifampin, Tuberculosis EMTREE drug terms dolutegravir, isoniazid, moxifloxacin, rifapentine, rifampicin, rifapentine, tuberculostatic agent EMTREE medical terms clinical outcome, disease elimination, Europe, European Medicines Agency, health care access, health care personnel, health program, high income country, human, Human immunodeficiency virus infected patient, Human immunodeficiency virus infection, Infection control, latent tuberculosis, letter, low income country, lung tuberculosis, medication compliance, middle income country, patent, randomized controlled trial (topic), treatment duration, combination drug therapy, Europe, tuberculosis